RPG Life Sciences reported a 16.5% revenue increase in the September quarter, even as regulatory price caps on cancer drugs hit industry headlines. The company clarified that its profit decline was linked to one-time acquisition costs rather than the new pricing mandate. Investors are now watching the integration of new API assets and upcoming contributions from its recent expansion into diabetes care.
RPG Life Sciences saw its revenue from operations grow 16.5 percent to ₹211.6 crore in the September quarter, even as the pharmaceutical sector faces increased regulatory scrutiny. Despite this strong top-line performance, net profit for the second quarter fell 37 percent to ₹23.29 crore compared to the same period last year. Management attributed this profit decline primarily to one-time costs associated with the recent acquisition of Actis and Raghava.
Regulatory Impact on Oncology Products
The company has addressed concerns regarding the National Pharmaceutical Pricing Authority's (NPPA) recent decision to cap trade margins at 30 percent for 137 non-scheduled cancer drugs. Managing Director Ashok Nair stated that the impact is expected to be minimal for the company. He explained that RPG Life Sciences was already supplying these products at pricing intended for institutions, meaning the price reduction effectively transfers the margin to hospitals rather than impacting the manufacturer’s internal revenue. This perspective suggests that the company’s core sales model for these oncology treatments remains largely unaffected by the mandate.
Integration of API Assets
The acquisition of Actis and Raghava is a significant part of the company's growth strategy. These assets have been integrated into a newly created division, RPG Active Pharma. While the acquired sites contributed only ₹0.5 crore to the revenue in the recent quarter due to the timing of the deal closure in late September, the company expects them to provide a fuller revenue contribution starting in the third quarter. Investors may track how quickly this new division reaches full capacity and whether it helps stabilize profit margins in the coming months.
Portfolio Expansion and Outlook
Beyond current operations, the company is diversifying its portfolio to address the chronic disease segment. In October, the firm launched semaglutide, a treatment aimed at the diabetes and obesity market. This move indicates a focus on high-growth segments to counter the challenging pricing environment currently impacting the domestic pharmaceutical industry. For shareholders, the key monitorable will be whether profit margins recover as the one-time integration expenses fade and the new API facilities and product launches begin to contribute more meaningfully to the bottom line.